STRATEC SE : No turn for the better – reduced guidance
>Weak second quarter on top line - Stratec reported preliminary H1 2023 revenues of € 125m (-8.9% y-o-y, -9.1% in constant currencies), which translate to Q2 revenues of € 64.5m compared to our forecast of € 69.5m. The corresponding miss to our second quarter revenues forecast and consensus was at around 10%. The company mentioned revised order forecasts of customers, destocking of customers post the pandemic, delivery backlogs with a new system for a veterinary diagn...STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.